ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
2.480
-0.500 (-16.78%)
At close: Sep 12, 2025, 4:00 PM EDT
2.510
+0.030 (1.21%)
After-hours: Sep 12, 2025, 7:59 PM EDT
-16.78%
Market Cap729.82M
Revenue (ttm)527,000
Net Income (ttm)-72.47M
Shares Out 294.28M
EPS (ttm)-0.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,276,508
Open3.000
Previous Close2.980
Day's Range2.371 - 3.050
52-Week Range0.460 - 7.130
Beta1.79
AnalystsBuy
Price Target6.25 (+152.02%)
Earnings DateNov 11, 2025

About PROK

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 204
Stock Exchange NASDAQ
Ticker Symbol PROK
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for PROK stock is "Buy." The 12-month stock price target is $6.25, which is an increase of 152.02% from the latest price.

Price Target
$6.25
(152.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

ProKidney Corp. (NASDAQ:PROK) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Bruce Culleton - CEO & Director James Coulston - Chief Financi...

5 days ago - Seeking Alpha

ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript

ProKidney Corp. (NASDAQ:PROK) Citi's Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Bruce Culleton - CEO & Director Ethan Holdaway Conference Call Participant...

10 days ago - Seeking Alpha

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

17 days ago - GlobeNewsWire

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney ...

4 weeks ago - GlobeNewsWire

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

WINSTON-SALEM, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

2 months ago - GlobeNewsWire

Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%

Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on Augu...

2 months ago - Yahoo Finance

ProKidney: What's Happening With PROK Stock?

ProKidney Corp. (NASDAQ: PROK) has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study, which assesses rilparencel in patients suffering from chro...

2 months ago - Forbes

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

2 months ago - GlobeNewsWire

ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying

The stock of the day on Tuesday was ProKidney Corp.'s, as it was both the biggest gainer and the most actively traded on major U.S. exchanges, after the biotechnology company's diabetes treatment prod...

2 months ago - Market Watch

Gold Falls 1%; ProKidney Shares Spike Higher

U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday.

2 months ago - Benzinga

Why Is Penny Stock ProKidney Trading Higher On Tuesday?

ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.

2 months ago - Benzinga

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

WINSTON-SALEM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

2 months ago - GlobeNewsWire

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware

WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

2 months ago - GlobeNewsWire

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

WINSTON-SALEM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidn...

4 months ago - GlobeNewsWire

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

WINSTON-SALEM, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD...

6 months ago - GlobeNewsWire

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm

NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK) breached their fi...

8 months ago - PRNewsWire

2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment

Rilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as we...

8 months ago - Seeking Alpha

ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy c...

10 months ago - GlobeNewsWire

ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

WINSTON-SALEM, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

10 months ago - GlobeNewsWire

ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference

WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy c...

11 months ago - GlobeNewsWire

ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024

WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...

11 months ago - GlobeNewsWire

ProKidney to Participate in the UBS Virtual Organ Restoration Day

WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy c...

1 year ago - GlobeNewsWire

ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a late clinical-stage biotech company focused on the development of a first-in-cl...

1 year ago - GlobeNewsWire

ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell t...

1 year ago - GlobeNewsWire

ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

WINSTON-SALEM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) --  ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic ki...

1 year ago - GlobeNewsWire